STERIS (NYSE:STE) Earns Overweight Rating from Stephens

STERIS (NYSE:STE)‘s stock had its “overweight” rating reiterated by research analysts at Stephens in a research report issued on Thursday,Benzinga reports. They presently have a $250.00 price target on the medical equipment provider’s stock. Stephens’ target price indicates a potential downside of 0.84% from the stock’s previous close.

Several other research firms have also recently weighed in on STE. Piper Sandler boosted their price objective on shares of STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. JMP Securities reissued a “market outperform” rating and issued a $265.00 price target on shares of STERIS in a report on Thursday, April 10th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a research note on Monday, April 7th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $265.00.

STERIS Stock Performance

NYSE STE opened at $252.12 on Thursday. STERIS has a twelve month low of $200.98 and a twelve month high of $252.20. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. The stock has a market cap of $24.77 billion, a P/E ratio of 53.53 and a beta of 0.96. The company’s 50-day simple moving average is $223.65 and its 200 day simple moving average is $219.15.

STERIS (NYSE:STE) last issued its quarterly earnings data on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.15. The company had revenue of $1.48 billion during the quarter, compared to analysts’ expectations of $1.47 billion. STERIS had a return on equity of 13.91% and a net margin of 8.66%. The business’s revenue was up 5.7% on a year-over-year basis. During the same period last year, the business earned $2.58 earnings per share. As a group, research analysts forecast that STERIS will post 9.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On STERIS

Institutional investors and hedge funds have recently modified their holdings of the company. Avalon Trust Co acquired a new stake in STERIS during the fourth quarter worth approximately $30,000. Grove Bank & Trust increased its holdings in shares of STERIS by 4,733.3% during the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 142 shares during the period. Human Investing LLC bought a new position in shares of STERIS during the fourth quarter worth approximately $31,000. Zions Bancorporation National Association UT bought a new position in shares of STERIS during the first quarter worth approximately $37,000. Finally, Anfield Capital Management LLC increased its holdings in shares of STERIS by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 91 shares during the period. 94.69% of the stock is owned by institutional investors.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.